Clinical Trial: STrategies for AntithRombotic Treatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07007143) titled 'STrategies for AntithRombotic Treatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant' on May 28.

Brief Summary: Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients unde...